Showing results (351-360 of 380) with videos related to
Sort By:
Pageof 38
Cell|August 21, 2020
IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor ProgressionAhmed Sadik, Luis F Somarribas Patterson, Selcen Öztürk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.European Journal of Cancer (Oxford, England : 1990)|September 5, 2025
Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patientsSelma Ugurel, Nessr Abu Rached, Thilo Gambichler, et al.Nature|July 31, 2020
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanomaUgur Sahin, Petra Oehm, Evelyna Derhovanessian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant TreatmentClaus Garbe, Ulrike Keim, Teresa Amaral, et al.European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapyAmelia M Taylor, Janet McKeown, Florentia Dimitriou, et al.European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.Nature Cancer|July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaRenáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.Pageof 38